@article{e6cebb91689c44ec9318b59593affd3e,
title = "Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?",
abstract = "The best therapy regimen for refractory obstetrical antiphospholipid syndrome remains to be determined. Additional treatments with steroids, plasma exchanges and immunoglobulins failed to show any beneficial effect. We present a case of a woman who had a better pregnancy outcome after the administration of hydroxychloroquine (HCQ) as additional treatment. Furthermore, we highlighted that HCQ was able to dramatically reduce the antiphospholipid antibodies levels.",
keywords = "Antibodies, Antiphospholipid, Antiphospholipid Syndrome, Pregnancy Outcome, Pregnancy, Pregnancy Complications, Hydroxychloroquine, Antibodies, Antiphospholipid, Antiphospholipid Syndrome, Pregnancy Outcome, Pregnancy, Pregnancy Complications, Hydroxychloroquine",
author = "{De Carolis}, Sara and Silvia Salvi and Antonio Lanzone and Angela Botta and di, {Pasquo E.} and Del, {Sordo G.} and C. Garufi and De, {Carolis M. P.}",
year = "2015",
doi = "10.1016/j.autrev.2015.04.010",
language = "English",
volume = "14",
pages = "760--762",
journal = "AUTOIMMUNITY REVIEWS",
issn = "1568-9972",
publisher = "Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010",
}